Safety of alitretinoin for severe refractory chronic hand eczema: Clinical studies and postmarketing surveillance

Abstract

Safety data collected in pivotal trials and postmarketing surveillance suggest that alitretinoin is well tolerated by patients with CHE with a relatively low incidence of serious reactions. The adverse reaction profile is congruent with reported effects of other marketed oral retinoids.